In 2025, Genscript Biotech completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Genscript Biotech has also provided a category-level breakdown for 15 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 19,520.21a | 39,376.8a | 48,821.78b | |
Total Scope 2 | ||||
Market-Based | 128,855a | 114,034.82a | 83,758.36b | |
Location-Based | 117,583.84a | 112,287.37a | 83,758.36b | |
Total Scope 3 | 848,471.11a | 387,028b | 314,658.76b | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 20.3436a | 66.2367a | 87.1071b |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Genscript Biotech amounted to 137,104.05 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Genscript Biotech decreased by 9.6%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2025, the total Scope 1 emissions of Genscript Biotech were 19,520.21 metric tons of CO₂ equivalent (tCO₂e).a
Since 2023, Genscript Biotech's Scope 1 emissions have decreased by 60.02%, reflecting a declining long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2024), Genscript Biotech's Scope 1 emissions decreased by 50.43%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2025, Genscript Biotech reported Scope 2 greenhouse gas (GHG) emissions of 128,855 tCO₂e using the market-based method and 117,583.84 tCO₂e using the location-based method.a
Since 2023, Genscript Biotech's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have increased by 40.38%, reflecting a rising long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2024), Genscript Biotech's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Genscript Biotech's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2025, Genscript Biotech reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2025, Genscript Biotech reported 848,471.11 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Genscript Biotech includes a breakdown across 15 of the 15 Scope 3 categories defined by the GHG Protocol, up from 0 in 2024, reflecting improved emissions accounting practices and greater transparency across the company's value chaina
In 2025, Genscript Biotech reported total Scope 3 emissions of 848,471.11 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 78.11% of these emissions originated from upstream activities such as purchased goods and capital goods, while 21.89% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2023, Genscript Biotech's Scope 3 emissions have increased by 169.65%, reflecting a rising long-term trend in Scope 3 emissions over time.ab
Compared to the previous year (2024), Genscript Biotech's Scope 3 emissions increased by 119.23%, suggesting that the company faced challenges in reducing emissions across its value chain.ab
In 2025, Genscript Biotech reported emissions for 15 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2025, the largest contributors to Genscript Biotech's Scope 3 emissions were:a
In 2025, Genscript Biotech reported Scope 1 greenhouse gas (GHG) emissions of 19,520.21 tCO₂e and total revenues of USD 960 millions. This translates into an emissions intensity of 20.34 tCO₂e per millions USD.a
In 2025, Genscript Biotech reported a Scope 1 emissions intensity of 20.34 tCO₂e per millions USD. Compared to the peer group median of 10.66, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2025, Genscript Biotech ranked 17 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Genscript Biotech is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2025, Genscript Biotech reported a total carbon footprint of 985,575.16 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 82.96% increase compared to 2024, suggesting a rise in emissions across its operations or value chain.ab
The largest contributor to Genscript Biotech's total carbon footprint was Scope 3 emissions, accounting for 86.09% of the company's total carbon footprint, followed by Scope 2 emissions at 11.93%.a